L3VLUP
ProSign in

BDTX · GILD in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

BDTXGILD
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • BDTX
  • GILD
010203040202120222023202420252026
Holders and value by quarter
QuarterBDTXGILD
Q3 20201 holders, $16m25 holders, $14.2bn
Q4 20203 holders, $37m27 holders, $13.4bn
Q1 20211 holders, $1.6m24 holders, $14.5bn
Q2 20212 holders, $2.6m18 holders, $14.9bn
Q3 20211 holders, $862k20 holders, $16.4bn
Q4 2021none listed holders, n.a.20 holders, $16.8bn
Q1 2022none listed holders, n.a.28 holders, $13.2bn
Q2 2022none listed holders, n.a.26 holders, $13.6bn
Q3 2022none listed holders, n.a.24 holders, $13.3bn
Q4 2022none listed holders, n.a.32 holders, $21.1bn
Q1 2023none listed holders, n.a.27 holders, $21.8bn
Q2 20231 holders, $252k24 holders, $20.7bn
Q3 20232 holders, $5.0m24 holders, $20.0bn
Q4 20231 holders, $4.4m22 holders, $21.5bn
Q1 2024none listed holders, n.a.30 holders, $20.3bn
Q2 2024none listed holders, n.a.28 holders, $18.5bn
Q3 2024none listed holders, n.a.29 holders, $24.2bn
Q4 2024none listed holders, n.a.28 holders, $25.9bn
Q1 2025none listed holders, n.a.33 holders, $32.0bn
Q2 2025none listed holders, n.a.27 holders, $30.9bn
Q3 2025none listed holders, n.a.23 holders, $29.4bn
Q4 20251 holders, $1.0m25 holders, $34.3bn
Q1 2026none listed holders, n.a.25 holders, $38.5bn
Q2 2026none listed holders, n.a.26 holders, $34.2bn
BDTX

Black Diamond Therapeutics Inc

Holders
0
Reported value
$0
Buyers
n.a.
Sellers
n.a.

No cross-section for this quarter.

Pharmaceuticals and biotechnologyBiological productsHealthcare: biopharma and medtech · L3VLUP
GILD

Gilead Sciences Inc

Holders
27
Reported value
$30.9bn
Buyers
18
Sellers
10

Breadth +8 among 95 comparable managers.

Pharmaceuticals and biotechnologyBiological productsHealthcare: biopharma and medtech · L3VLUP

Who holds both, Q2 2025

Among the 27 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Both (0)

No tracked manager lists every one of them.

Only BDTX (0)

None.

Only GILD (27)

Acadian Asset Management LLC, AllianceBernstein LP, AQR Capital Management LLC, Arrowstreet Capital LP, Balyasny Asset Management LLC, Bridgewater Associates LP, Capital Research Global Investors, Capital World Investors, Citadel Advisors LLC, D. E. Shaw & Co., Dodge & Cox, Fidelity (FMR LLC), Holocene Advisors LP, Invesco Ltd, Janus Henderson Group Ltd, Man Group PLC, Marshall Wace LLP, Millennium Management LLC, Neuberger Berman Group LLC, PDT Partners LLC, Renaissance Technologies LLC, Schonfeld Strategic Advisors LLC, Squarepoint Ops LLC, T. Rowe Price Associates Inc, Wellington Management Group LLP, and 2 more

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →